retatrutide triple agonist phase 2 nejm 2023 obesity results Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks obesity #retatrutide #weight #glp1 #nejm

10.18632/oncotarget.23055 28 ChenM.JiangY.SunY

General Information and Overviews of BPC-157 Examine.com Research Breakdown on BPC-157: Provides an overview of BPC-157's chemical structure, mechanism of action, and research findings

Saponins Saponins have been applied in the treatment of various diseases for many years in clinical practice

The weight loss effect depends specifically on AMY1R and AMY3R activation, as confirmed by a study in eBioMedicine that showed cagrilintide lowers body weight through these specific receptor subtypes in the brainstem

The world of metabolic health and weight management is full of different tools, each with a unique mechanism of action